Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the ...

Ms Botham highlighted her father's charity work through the Beefy's Charity Foundation, which supports several causes ...

Sarah Botham said it had "never been a secret" the independent crossbencher's attendance in Parliament would be limited due ...

These included Blood Cancer UK and the Batten Disease Family Association (BDFA), which raises awareness and funds research ...

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

NEW YORK – Neurogene on Monday said after the market closed that it will stop advancing NGN-101 as a treatment for CLN5 Batten disease, a very rare genetic disorder. The New York-based company said it ...

Separately, Neurogene also shared its plans to discontinue development of a gene therapy for Batten disease after the Food ...

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

In a new study, a team of researchers, including Anneliene Jonker, has published, in Nature Reviews Drug Discovery, the first ...

Alzheimer’s disease may cause cognitive complications like severe memory loss, mental health complications like depression, and physical complications like reduced mobility. Alzheimer’s ...